AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7914235 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated IFN alpha (i-IFN alpha) without HIV-1 antigens (group A)
Number of subjects: 22
Study 7914235 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group D)
Number of subjects: 22
Study 3202097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose coadministration with calcium at 222 mmol
Number of subjects: 10
Study 3202097 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose coadministration with calcium at 0 mmol (control)
Number of subjects: 10
Study 3202097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose coadministration with calcium at 56 mmol
Number of subjects: 10
Study 3202097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose coadministration with calcium at 444 mmol
Number of subjects: 10
Study 31708060 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Intervention (II)
Number of subjects: 507
Study 31708060 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Educational (EE) materials
Number of subjects: 507
Study 28359280 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free mouthrinse containing essential oils (Listerine Zero)
Number of subjects: 21
Study 28359280 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based essential oils mouthrinse (EO+)
Number of subjects: 21
Study 28359280 — intervention group
Group type: COMPARATOR
Intervention: 0.20% chlorhexidine mouthrinse (CHX)
Number of subjects: 21
Study 28359280 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (saline)
Number of subjects: 21
Study 25185099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 1144
Study 25185099 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 1144
Study 24297189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with pegylated interferon‐α2a (135 µg weekly) plus ribavirin (200 mg daily)
Number of subjects: 205
Study 24297189 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon‐α2a (135 µg weekly) monotherapy
Number of subjects: 205
Study 24297189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with pegylated interferon‐α2a plus ribavirin
Number of subjects: 205
Study 24297189 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon‐α2a monotherapy
Number of subjects: 205
Study 21600688 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human luteinizing hormone (rhLH) 37.5 IU
Number of subjects: 187
Study 21600688 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human luteinizing hormone (rhLH) 75 IU
Number of subjects: 187
Study 21600688 — intervention group
Group type: COMPARATOR
Intervention: recombinant human follicle‐stimulating hormone (rhFSH) alone
Number of subjects: 187
Study 18841382 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendicitis-score group
Number of subjects: 126
Study 18841382 — intervention group
Group type: COMPARATOR
Intervention: No-score group
Number of subjects: 126
Study 18841382 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 126
Study 16764872 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment of miscarriage with 200 mg of mifepristone and 0.8 mg of misoprostol 1‐3 days after the event
Number of subjects: 98
Study 16764872 — intervention group
Group type: COMPARATOR
Intervention: Surgical uterine evacuation
Number of subjects: 98
Study 14754942 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric CI therapy
Number of subjects: 18
Study 14754942 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 18
Study 11751485 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 80 mg/m(2) as i.v. bolus followed by paclitaxel 200 mg/m(2) as a 24-h infusion and then cyclophosphamide 3.0 g/m(2) as a 1-h infusion (arm A)
Number of subjects: 42
Study 11751485 — intervention group
Group type: COMPARATOR
Intervention: Concurrent paclitaxel and cyclophosphamide at the same doses (arm B)
Number of subjects: 42
Study 9403288 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose 5 mg t.i.d.
Number of subjects: 12
Study 9403288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10779290 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 200 microg/day
Number of subjects: 39
Study 10779290 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 400 microg/day
Number of subjects: 39
Study 10779290 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) 30 mg/day
Number of subjects: 39
Study 3541724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 181
Study 3541724 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 181
Study 3541724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 31847602 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening feeding (4 weeks)
Number of subjects: 22
Study 31847602 — intervention group
Group type: COMPARATOR
Intervention: Morning feeding (4 weeks)
Number of subjects: 22
Study 31847602 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AM vs PM feeding
Number of subjects: 22
Study 31274244 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlobar CMB
Number of subjects: 344
Study 31274244 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobar CMB
Number of subjects: 344
Study 31274244 — intervention group
Group type: EXPERIMENTAL
Intervention: CMB
Number of subjects: 344
Study 31274244 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe confluent WMH
Number of subjects: 344
Study 31274244 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and sex
Number of subjects: 344
Study 28265762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence
Number of subjects: 456
Study 28265762 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 456
Study 28265762 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Mediterranean diet and physical activity
Number of subjects: 456
Study 26002536 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based didactic instruction
Number of subjects: 39
Study 26002536 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity simulation activities
Number of subjects: 39
Study 26002536 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation activities
Number of subjects: 39
Study 26002536 — intervention group
Group type: COMPARATOR
Intervention: Control (lecture only)
Number of subjects: 39
Study 23872824 — intervention group
Group type: EXPERIMENTAL
Intervention: danoprevir/r
Number of subjects: 54
Study 23872824 — intervention group
Group type: COMPARATOR
Intervention: placebo/r
Number of subjects: 54
Study 21572328 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin arm
Number of subjects: 1200
Study 21572328 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care-only arm
Number of subjects: 1200
Study 19650947 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled pharmacotherapy
Number of subjects: 0
Study 19650947 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for inhaled pharmacotherapy
Number of subjects: 0
Study 16615287 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal surgery
Number of subjects: 20
Study 16615287 — intervention group
Group type: COMPARATOR
Intervention: Orthopaedic surgery
Number of subjects: 20
Study 14571186 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir, zidovudine, and lamivudine
Number of subjects: 33
Study 14571186 — intervention group
Group type: COMPARATOR
Intervention: Post-study regimen
Number of subjects: 33
Study 14571186 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir, zidovudine, and lamivudine (combined on-study and post-study)
Number of subjects: 33
Study 10729391 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose acetylcholine
Number of subjects: 31
Study 10729391 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose acetylcholine
Number of subjects: 31
Study 10729391 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8-lymphocytes expressing ICAM-1
Number of subjects: 31
Study 10729391 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to oxidized low-density lipoprotein
Number of subjects: 31
Study 10729391 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 31
Study 8888218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus tracking with 120 mL of contrast material
Number of subjects: 120
Study 8888218 — intervention group
Group type: COMPARATOR
Intervention: Fixed scanning delay with 120 mL of contrast material
Number of subjects: 120
Study 8888218 — intervention group
Group type: COMPARATOR
Intervention: Bolus tracking with 100 mL of contrast material
Number of subjects: 120
Study 8888218 — intervention group
Group type: COMPARATOR
Intervention: Fixed scanning delay with 100 mL of contrast material
Number of subjects: 120
Study 1490430 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine
Number of subjects: 63
Study 1490430 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 63
Study 3859587 — intervention group
Group type: EXPERIMENTAL
Intervention: epirubicin 85 mg/m2
Number of subjects: 54
Study 3859587 — intervention group
Group type: COMPARATOR
Intervention: doxorubicin 60 mg/m2
Number of subjects: 54
Study 3859587 — intervention group
Group type: EXPERIMENTAL
Intervention: epirubicin
Number of subjects: 54
Study 3859587 — intervention group
Group type: COMPARATOR
Intervention: doxorubicin
Number of subjects: 54
Study 28181772 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive method for evaluating pubertal status based on anthropometric variables
Number of subjects: 206
Study 28181772 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation sample (N=52)
Number of subjects: 206
Study 26467038 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration (CWI)
Number of subjects: 54
Study 26467038 — intervention group
Group type: COMPARATOR
Intervention: Single-injection transversus abdominis plane (TAP) block
Number of subjects: 54
Study 25182605 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidified ventilation
Number of subjects: 50
Study 25182605 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 50
Study 23066868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecabet sodium quadruple therapy
Number of subjects: 311
Study 23066868 — intervention group
Group type: COMPARATOR
Intervention: Bismuth quadruple therapy
Number of subjects: 311
Study 20464599 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan
Number of subjects: 0
Study 20464599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18822996 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram at Level 1
Number of subjects: 0
Study 18822996 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent treatment options at Levels 2-4 (randomized and open label)
Number of subjects: 0
Study 18822996 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who did not reach full remission
Number of subjects: 0
Study 16125588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate 2.4 mg/kg bodyweight given as a bolus at 0, 12, and 24 h, then daily
Number of subjects: 1461
Study 11849659 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d for 6 weeks
Number of subjects: 63
Study 11849659 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin dosage variations (mg/kg/day)
Number of subjects: 63
Study 11849659 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo E polymorphism
Number of subjects: 63
Study 12202047 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (2.5‐ and 5‐mg doses)
Number of subjects: 7981
Study 12202047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7981
Study 9517503 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cytarabine and etoposide (HIDAC‐3‐7)
Number of subjects: 0
Study 9517503 — intervention group
Group type: COMPARATOR
Intervention: Standard dose combination (7‐3‐7)
Number of subjects: 0
Study 8038354 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 250
Study 8038354 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg daily
Number of subjects: 250
Study 8038354 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg nightly
Number of subjects: 250
Study 3398651 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam cream (0.5%, 1%, 1.5%)
Number of subjects: 5
Study 3398651 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin cream (5%)
Number of subjects: 5
Study 3398651 — intervention group
Group type: EXPERIMENTAL
Intervention: Etofenamate gel (1%)
Number of subjects: 5
Study 3398651 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine cream (5%)
Number of subjects: 5
Study 3398651 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam gel (1%)
Number of subjects: 5
Study 30995824 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin Propionate Ester (IPE) incorporated into food products (10 g/d for six days)
Number of subjects: 21
Study 30995824 — intervention group
Group type: COMPARATOR
Intervention: Control (un-supplemented food products)
Number of subjects: 21
Study 30995824 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin Propionate Ester (IPE) incorporated into food products
Number of subjects: 21
Study 29159176 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate nostril breathing exercise for 15 minutes
Number of subjects: 30
Study 29159176 — intervention group
Group type: COMPARATOR
Intervention: Control group (quiet room)
Number of subjects: 30
Study 25555445 — intervention group
Group type: EXPERIMENTAL
Intervention: Art, massage, or music therapy employed in hospices
Number of subjects: 591
Study 25555445 — intervention group
Group type: COMPARATOR
Intervention: Larger hospices
Number of subjects: 591
Study 25555445 — intervention group
Group type: COMPARATOR
Intervention: For-profit hospices
Number of subjects: 591
Study 25555445 — intervention group
Group type: COMPARATOR
Intervention: Hospices in the Mountain/Pacific region
Number of subjects: 591
Study 23824152 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 M gadobutrol
Number of subjects: 51
Study 23824152 — intervention group
Group type: COMPARATOR
Intervention: 0.5 M gadoteridol
Number of subjects: 51
Study 21624490 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FM 320/9 μg
Number of subjects: 40
Study 21624490 — intervention group
Group type: COMPARATOR
Intervention: FP/SM 250/50 μg
Number of subjects: 40
Study 18774274 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT plus clonazepam
Number of subjects: 58
Study 18774274 — intervention group
Group type: COMPARATOR
Intervention: clonazepam
Number of subjects: 58
Study 16786913 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene (IS) approach
Number of subjects: 81
Study 16786913 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene (ISCM) approach
Number of subjects: 81
Study 12658666 — intervention group
Group type: EXPERIMENTAL
Intervention: Media literacy program
Number of subjects: 86
Study 12658666 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem program
Number of subjects: 86
Study 12658666 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 10934666 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S.-brand warfarin sodium tablet (5 mg)
Number of subjects: 24
Study 10934666 — intervention group
Group type: COMPARATOR
Intervention: Generic warfarin product (5 mg)
Number of subjects: 24
Study 9795574 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education using simple line drawings of reproductive organs and signs of STDs; method not quantified in terms of dosage or duration.
Number of subjects: 0
Study 9795574 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based health education methods; specifics not quantified.
Number of subjects: 0
Study 1567574 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) administered at 20 mg/kg/day plus 100 mg/kg/day for 21 days.
Number of subjects: 163
Study 1567574 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine administered at 4 mg/kg/day for 21 days.
Number of subjects: 163
Study 1567574 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in therapy due to failure to respond.
Number of subjects: 163
Study 1567574 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in therapy due to toxicity.
Number of subjects: 163
Study 29249166 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg b.i.d.
Number of subjects: 12626
Study 29249166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12626
Study 29031492 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted Symptom Management (ASM) consisting of automated symptom monitoring by interactive voice recording or Internet and prompted pain and mood self‐management
Number of subjects: 294
Study 29031492 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive Symptom Management (CSM) which combines ASM with optimized medication management delivered by a nurse-physician specialist team and facilitated mental health care
Number of subjects: 294
Study 29031492 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted Symptom Management (ASM)
Number of subjects: 294
Study 29031492 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive Symptom Management (CSM)
Number of subjects: 294
Study 27451854 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (NADA protocol)
Number of subjects: 280
Study 27451854 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (local protocol)
Number of subjects: 280
Study 27451854 — intervention group
Group type: COMPARATOR
Intervention: Relaxation (control)
Number of subjects: 280
Study 23926046 — intervention group
Group type: EXPERIMENTAL
Intervention: Frustration induction
Number of subjects: 330
Study 23926046 — intervention group
Group type: COMPARATOR
Intervention: No frustration induction
Number of subjects: 330
Study 21965517 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise-based cardiac rehabilitation (group T)
Number of subjects: 50
Study 21965517 — intervention group
Group type: COMPARATOR
Intervention: Generic instructions for maintaining physical activity (group C)
Number of subjects: 50
Study 20493487 — intervention group
Group type: EXPERIMENTAL
Intervention: FICE (Fuji Intelligent Color Enhancement)
Number of subjects: 359
Study 20493487 — intervention group
Group type: COMPARATOR
Intervention: WL (Conventional White-Light Colonoscopy)
Number of subjects: 359
Study 17608233 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Yangnao capsule
Number of subjects: 0
Study 17608233 — intervention group
Group type: COMPARATOR
Intervention: Dukexi slice (control)
Number of subjects: 0
Study 16125497 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (higher doses in the upper quartile)
Number of subjects: 691
Study 16125497 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (both dosage levels)
Number of subjects: 691
Study 16125497 — intervention group
Group type: COMPARATOR
Intervention: Beta blockers (lower doses in the lower 3 quartiles)
Number of subjects: 691
Study 12244291 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.50% (1 mg/kg)
Number of subjects: 45
Study 12244291 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic bupivacaine 0.50% (1 mg/kg)
Number of subjects: 45
Study 12244291 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.75% (1.4 mg/kg)
Number of subjects: 45
Study 10334137 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-onset asthma while employed
Number of subjects: 150
Study 10334137 — intervention group
Group type: EXPERIMENTAL
Intervention: Recrudescence of previously quiescent childhood-onset asthma during employment
Number of subjects: 150
Study 10334137 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupations at increased risk of occupational asthma initiation
Number of subjects: 150
Study 10334137 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupations at increased risk of exposures aggravating asthma
Number of subjects: 150
Study 7789139 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arms (specific intervention details not provided)
Number of subjects: 0
Study 7789139 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study 1962904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (FR‐860)
Number of subjects: 61
Study 1962904 — intervention group
Group type: COMPARATOR
Intervention: Conventional heparin
Number of subjects: 61
Study 7272152 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 12
Study 7272152 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 12
Study 7272152 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine and Metoclopramide (combined administration)
Number of subjects: 12
Study 31589541 — intervention group
Group type: EXPERIMENTAL
Intervention: TD group
Number of subjects: 3
Study 31589541 — intervention group
Group type: EXPERIMENTAL
Intervention: SSD-contrast group
Number of subjects: 3
Study 31589541 — intervention group
Group type: COMPARATOR
Intervention: SSD-collapse group
Number of subjects: 3
Study 31589541 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert contrast
Number of subjects: 3
Study 28822660 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire exchange (GE)
Number of subjects: 678
Study 28822660 — intervention group
Group type: COMPARATOR
Intervention: Catheter removal (CR)
Number of subjects: 678
Study 26740065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fugl-Meyer Assessment of the lower extremity (FMA-LE)
Number of subjects: 535
Study 26740065 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasch analysis rating scale model
Number of subjects: 535
Study 25078374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-germinated brown rice (PGBR)
Number of subjects: 60
Study 25078374 — intervention group
Group type: COMPARATOR
Intervention: White rice (WR)
Number of subjects: 60
Study 21751879 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical N-acetyl-cysteine (NAC) 5%
Number of subjects: 20